Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Pozelimab, a Human Antibody Against Complement Factor C5, Demonstrates Robust Inhibition of Alternative Complement Activity Both in Normal Human Serum and in Phase I Normal Healthy Volunteers

Kishor Devalaraja-Narashimha, PhD DVM, Yan G Ni, PhD, Cong Huang, Ming-Dauh Wang, PhD, Umesh Chaudhari, MD, Srinivasa Prasad, PhD, Olivier Harari, MD PhD, Andrew J Rankin, PhD, Lori Morton, PhD, Jonathan Weyne, MD

Blood (2019) 134 (Supplement_1): 2278.

https://doi.org/10.1182/blood-2019-129865

Published: 2019

Journal Articles

A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study of the Pharmacokinetics and Pharmacodynamics of REGN3918, a Human Antibody Against Complement Factor C5, in Healthy Volunteers

Jonathan Weyne, MD, Yan Ni, PhD, Richard DelGizzi, PA, MS, Stephen Godin, PhD, Lori Morton, PhD, Srinivasa Prasad, PhD, Andrew J Rankin, PhD, Melissa Simek-Lemos, MPH, ming-Dauh Wang, PhD, Ronda Rippley, PhD, Olivier Harari, MD PhD

Blood (2018) 132 (Supplement 1): 1039.

https://doi.org/10.1182/blood-2018-99-112262

Published: 2018

Journal Articles

AV513 Promotes Tissue Factor-Mediated Coagulation in Fresh Human Whole Blood from Severe and Moderate Hemophilia a Subjects.

Jerry Sherman Powell, MD, Sabine Knappe, PhD, Janet A Harrison, BS, Susannah Patarroyo-White, BS, Kirk Johnson, PhD, Srinivasa Prasad, PhD

Blood (2008) 112 (11): 1223.

https://doi.org/10.1182/blood.V112.11.1223.1223

Published: 2008

Journal Articles

Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A

Srinivasa Prasad, David Lillicrap, Andrea Labelle, Sabine Knappe, Tracy Keller, Erin Burnett, Sandra Powell, Kirk W. Johnson

Blood (2008) 111 (2): 672–679.

https://doi.org/10.1182/blood-2007-07-098913

Published: 2008

Journal Articles

AV513 Enhances Tissue Factor Activity by Inhibiting TFPI in Hemophilia A Plasma: Potential TFPI Target Sites and Potentiation of Factor VIII Activity.

Sabine Knappe, PhD, Nicholas Kripalani, BS, Susannah Patarroyo-White, BS, Kirk W. Johnson, PhD, Srinivasa Prasad, PhD

Blood (2007) 110 (11): 497.

https://doi.org/10.1182/blood.V110.11.497.497

Published: 2007

NARROW

Pozelimab, a Human Antibody Against Complement Factor C5, Demonstrates Robust Inhibition of Alternative Complement Activity Both in Normal Human Serum and in Phase I Normal Healthy Volunteers

A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study of the Pharmacokinetics and Pharmacodynamics of REGN3918, a Human Antibody Against Complement Factor C5, in Healthy Volunteers

AV513 Promotes Tissue Factor-Mediated Coagulation in Fresh Human Whole Blood from Severe and Moderate Hemophilia a Subjects.

Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A

AV513 Enhances Tissue Factor Activity by Inhibiting TFPI in Hemophilia A Plasma: Potential TFPI Target Sites and Potentiation of Factor VIII Activity.

Email alerts

ASH Publications

American Society of Hematology

Pozelimab, a Human Antibody Against Complement Factor C5, Demonstrates Robust Inhibition of Alternative Complement Activity Both in Normal Human Serum and in Phase I Normal Healthy Volunteers

A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study of the Pharmacokinetics and Pharmacodynamics of REGN3918, a Human Antibody Against Complement Factor C5, in Healthy Volunteers

AV513 Promotes Tissue Factor-Mediated Coagulation in Fresh Human Whole Blood from Severe and Moderate Hemophilia a Subjects.

Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A

AV513 Enhances Tissue Factor Activity by Inhibiting TFPI in Hemophilia A Plasma: Potential TFPI Target Sites and Potentiation of Factor VIII Activity.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only